TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/28/2025
Back to search
Official data from USPTO
TT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
05/03/2025
Classification
Registered
Trademark type
Combined
Nice classes
5, 9, 42, 44
Filing date
07/12/2023
Registration date
03/11/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/11/2025
Last transaction
05/03/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
99
Owner location
Cambridge, GB
Examiner
ANDERSON, DANIELLE
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of an abstract design in the color light blue, within which is a white upside down letter T on top of a white right side up letter T.
Holders and representatives
Holders
T-Therapeutics Limited
Representatives
Stacy J. Grossman SGIP
Technical classification
Nice Classes
Class 5Class 9Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; chemical and biological pharmaceutical preparations for medical purposesfor protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; chemical preparations for use in DNA analysis for medical purposes; DNA synthesis inhibitors for medical purposespharmaceutical preparations for protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; biological preparations for the treatment of cancer; biological preparations for the treatment of viral and bacterial infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use for the treatment of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; immunotherapeutic drugs namelypharmaceutical preparations for protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; reagents for medical use; diagnostic preparations for medical use; diagnostic reagents for medical use; preparations for detecting genetic predispositions for medical purposes
Class 9
Downloadable computer software for use in collectinganalyzing and organizing data in the field of pharmaceuticalsbiopharmaceutical drug development and genome engineering; downloadable computer software for use in collectinganalyzing and organizing data in the field of scientific and pharmaceutical research and development; downloadable software for scientific modelling of pharmaceuticals in the field of scientific and pharmaceutical research and development; downloadable software for pharmaceutical modelling; downloadable software for research and development in the nature of collectinganalyzing and organizing data in the field of antibodies; devices for analyzing genome informationlaboratory devices for detecting genetic sequences; downloadable software for performing gene sequencing research and visualizationscientific analysis of genetic sequences; downloadable software for the managinganalysisvisualization of biological data
Class 42
Scientific and technological servicesscientific research and development in the field of pharmaceuticals for genome engineering and biopharmaceutical drug development for protection from infectionscancerdisease or inflammation; technical research in the field of pharmaceutical studies; design and development of computer hardware and software; platform as a service (PAAS) featuring computer software platforms for use in database management in the field of pharmaceuticalsbiopharmaceutical drug development and genome engineering; platform as a service (PAAS) featuring DNA analysis software platforms; software as a service (SAAS) services featuring software for use in database management in the field of pharmaceuticalsbiopharmaceutical drug development and genome engineering; software as a service (SAAS) services featuring DNA analysis software; provision of online non-downloadable software for the managementvisualization and analysis of biological data for the purposes of biomolecular research and the design and engineering of biomolecular products; DNA analysis services in the field of DNA sequencing for scientific research; provision of a web hosting platform for the analysis of DNA sequencing data for scientific research purposes and diagnostic and treatment purposes
Class 44
Medical services; diagnostic and prognostic medical services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health care services relating to DNAgeneticsgenetic pathogen testing for diagnostic or treatment purposes; medical screening and assaying in the nature of medical laboratory analysis services relating to the treatment of persons; DNA screening for medical purposes; DNA analysis services in the field of DNA sequencing for diagnostic and treatment purposes provided by medical laboratories
Publications
History of USPTO decisions and trademark events.
41 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/28/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/28/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/28/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/28/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/11/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
03/11/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/21/2025
PUBO
PUBLISHED FOR OPPOSITION
01/21/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/15/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/27/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
12/27/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/27/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
12/27/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/27/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/16/2024
GNFR
FINAL REFUSAL E-MAILED
12/16/2024
CNFR
FINAL REFUSAL WRITTEN
12/16/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/07/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/07/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/07/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
10/09/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
10/09/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/11/2024
GNRT
NON-FINAL ACTION E-MAILED
07/11/2024
CNRT
NON-FINAL ACTION WRITTEN
07/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/11/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/11/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/31/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/31/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/31/2024
GRML
CORRESPONDENCE E-MAILED
03/27/2024
CNRT
NON-FINAL ACTION WRITTEN
03/27/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/27/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/27/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/27/2024
DOCK
ASSIGNED TO EXAMINER
03/20/2024
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/11/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/10/2023
NWAP
NEW APPLICATION ENTERED
07/15/2023
Continuous trademark protection
Get notified about every new filing that threatens TT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.